Severity: Warning
Message: fopen(/var/lib/php/sessions/ci_session1umgi67t94o5nomra5j5o983i0crla51): Failed to open stream: No space left on device
Filename: drivers/Session_files_driver.php
Line Number: 177
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
Severity: Warning
Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)
Filename: Session/Session.php
Line Number: 137
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
Unlabelled: According the mass spirometry, every third person over forty years old, suffer from COPD in Poland. Prophylaxis, early detection and proper treatment are necessary for the limitation of group of patients with severe COPD in the future. We analyzed the usage of particular group of medicines and estimated conformability of COPD treatment with actual recommendations.
Material And Methods: We included 125 subjects--26% women (n = 33), and 74% men (n = 92). Mean age was 62 +/- 10. Current smokers were 46% (n = 58) with mean time of smoking was 28 +/- 14 pack-years, ex-smokers 41% (n = 51), non-smokers 13% (n = 16). We recorded the treatment way and HbCO level in expired air. Spirometry and flow-volume test were provided. We used Statistica program for results statistical analysis.
Results: Usually, patients with mild COPD are treated with theophilline (49%), long-acting beta 2-agonists (40%), short-acting beta 2-agonists (35%), inhaled steroids and anticholinergics (24%). In mild-severe and severe form of COPD are used: theophilline (50%), short-acting beta 2-agonists (40%), long-acting beta 2-agonists (27%), inhaled steroids (19%) and anticholinergics (12%). 8.1 subjects with mild, 1.7% with mild-severe and 5.5% with severe COPD are treated with recommended connection of anticholinergic and long-acting beta 2-agonist.
Conclusions: Mostly theophilline and short-acting beta 2-agonists are used. Anticholinergics are used too seldom. COPD treatment is insufficient and inconsistent with actual recommendations. Only 1.7 to 5.5% patients are treated with recommended combination of anticholinergic and long-acting beta 2-agonist.
Download full-text PDF |
Source |
---|
Zhonghua Jie He He Hu Xi Za Zhi
March 2025
Bronchial asthma (asthma) is a common chronic respiratory disease. Standardized diagnosis, treatment and effective clinical management are critical to improving asthma control, improving patients' quality of life, and reducing the disease burden. Based on the latest evidence-based research from both domestic and international references, the Asthma Group of the Chinese Thoracic Society has revised the " ()".
View Article and Find Full Text PDFPediatr Crit Care Med
March 2025
Department of Pediatrics, Division of Critical Care, University of Utah, Salt Lake City, UT.
Objectives: Describe β2-agonists, steroids, hypertonic saline (HTS), n-acetylcysteine (NAC), and dornase alfa (DA) use to treat bronchiolitis, factors associated with use, and associations between use and PICU length of stay (LOS).
Design: Retrospective, multicenter cohort study.
Setting: PICUs in the Pediatric Health Information System database.
Introduction: So far, there is no direct comparison between inhaled corticosteroids (ICS) monotherapy and ICS-long acting beta-2 agonists (LABA) fixed-dose combination therapies in 6-11-year-old children with persistent asthma. The primary objective of this study is to compare ICS monotherapy and ICS-LABA fixed-dose combination therapies for the frequency of exacerbations requiring systemic corticosteroids (CS).
Methods: Patients aged 6-11 years diagnosed with persistent asthma at steps 2-4 of treatment, prescribed daily ICS-containing treatment (fluticasone propionate (FP), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (BUD/F)), and followed for at least one year at our institution from January 2021 to January 2024 were included.
BMJ Open Respir Res
February 2025
Pharmacology, Faculty of Medicine, University of Colombo, Colombo, Western Province, Sri Lanka.
Background: Inhaled corticosteroids (ICS) alone, or combined with long-acting beta-agonist (LABA), are recommended for chronic asthma. Limited access to inhaled medications hinders effective control of asthma in low-income and middle-income countries.
Objective: This study aimed to compare the effectiveness of inhaled therapies in a cohort of adult patients with asthma who were receiving treatment in a tertiary hospital in Northern Sri Lanka.
NPJ Prim Care Respir Med
February 2025
Adelphi Real World, Bollington, Cheshire, UK.
Inhaled corticosteroids (ICS) plus long-acting β-agonists (LABA) are recommended for maintenance-only or maintenance and reliever therapy (MART) in patients with asthma. However, real-world data on ICS/LABA as maintenance-only or MART are limited. This study characterized clinical, economic, and humanistic burdens of asthma in Canada, China, Europe, Japan, and the US, using data collected from patients and physicians via a cross-sectional survey (Asthma Disease Specific Programme).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!